Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ.
Palmieri C, et al.
Oncotarget. 2016 Mar 15;7(11):13209-20. doi: 10.18632/oncotarget.4801.
Oncotarget. 2016.
PMID: 26334099
Free PMC article.